This page is intended to provide access to U.S. Securities and Exchange Commission (SEC) filings for MapLight Therapeutics, Inc. (Nasdaq: MPLT), a clinical-stage biopharmaceutical company focused on central nervous system disorders. While no specific filings are listed in the available data here, as a Nasdaq-listed issuer MapLight has described an initial public offering and a concurrent private placement conducted under an effective registration statement filed with the SEC.
In general, SEC filings for a company like MapLight can include annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe material events such as clinical trial updates, financing transactions, or significant collaborations. Registration statements and prospectuses related to offerings, such as the IPO MapLight has referenced, also form part of the company’s regulatory record.
For a clinical-stage biopharmaceutical company, these filings typically discuss the status of product candidates like ML-007C-MA, ML-004, ML-021 and ML-009, outline clinical development plans, and describe risk factors related to central nervous system drug development. They may also provide details on research and development expenses, cash resources from offerings and private placements, and other financial information.
Stock Titan’s platform enhances access to such documents by pairing real-time updates from the SEC’s EDGAR system with AI-powered summaries. These tools are designed to help readers interpret lengthy filings, highlight key topics such as clinical trial disclosures, financing terms, and collaboration agreements, and locate information about insider transactions reported on Form 4 when available.
MapLight Therapeutics, Inc. (MPLT) reported that its General Counsel, Kristopher Hanson, received equity awards on August 17, 2026. He was granted 31,395 stock options with an exercise price of $11.245 per share, expiring August 16, 2036, and a separate award of 7,730 restricted stock units (RSUs). The options and RSUs vest over time, beginning July 1, 2027, subject to his continued service, and his direct voting common stock holdings increased to 153,553 shares after the RSU grant.
MapLight Therapeutics, Inc. (MPLT) reported equity compensation awards to its Chief Medical Officer, Erin Pennock Foff. She received an option for 54,240 shares of voting common stock at an exercise price of $11.245 per share, expiring on August 16, 2036, and a restricted stock unit award covering 13,360 shares. Both awards vest over time subject to continued service, and following these grants she directly holds 312,261 shares of voting common stock.
MapLight Therapeutics, Inc. (MPLT) reported that its Chief Executive Officer and director, Christopher A. Kroeger, received equity awards on August 17, 2026. He was granted an option to purchase 93,955 shares of voting common stock at an exercise price of $11.245 per share, expiring August 16, 2036; one quarter of these option shares vest on July 1, 2027, and the rest in equal monthly installments thereafter, subject to continued service. He also received 23,145 restricted stock units, each representing one share of voting common stock, with one quarter vesting on July 1, 2027 and the remainder in equal quarterly installments, also subject to continued service. Following these awards he directly holds 1,269,600 shares of voting common stock, and an additional 101,190 shares are held indirectly through the C&M Kroeger Nominee Trust, where he and his spouse serve as co-trustees with voting and dispositive power.
MapLight Therapeutics, Inc. (MPLT) reported that 10% owner Catalyst4, Inc. purchased 4,400,000 shares of Voting Common Stock and warrants for 2,928,686 shares on August 14, 2026 at around $11.38 per share. The warrants are immediately exercisable at $0.0001 per share but include a 49.99% beneficial ownership cap and do not expire until exercised in full. After these purchases, Catalyst4 indirectly holds 25,306,689 shares of Voting Common Stock, with voting and dispositive power shared by its directors, who each disclaim beneficial ownership.
MapLight Therapeutics, Inc. (MPLT) is the subject of this amended Schedule 13D, which updates the ownership position of Catalyst4, Inc. and related reporting persons following a private investment in public equity (PIPE). On August 13, 2026, Catalyst4 agreed to purchase 4,400,000 shares of MapLight voting common stock plus accompanying Pre-Funded Warrants to acquire up to 2,928,686 additional shares, at a purchase price of $11.38 per share of common stock; the warrant price equals that amount minus $0.0001 per underlying share. The PIPE closed on August 14, 2026 for an aggregate purchase price of $83,400,153.82, funded from Catalyst4’s working capital. Catalyst4 and affiliated reporting persons now report beneficial ownership of 27,536,011 shares, or 49.9% of MapLight’s voting common stock, based on 55,077,530 shares deemed outstanding, including 2,229,322 warrant shares exercisable within 60 days, subject to a 49.99% beneficial ownership cap.
MapLight Therapeutics, Inc. is a clinical-stage CNS biopharmaceutical company advancing lead candidate ML-007C-MA for schizophrenia and Alzheimer’s disease psychosis and ML-004 for autism spectrum disorder. In July 2026 it reported positive Phase 2 schizophrenia results (ZEPHYR) and Phase 2 topline data in ASD (IRIS).
For the six months ended June 30, 2026, the company recorded a net loss of $120.9 million, compared with $52.2 million a year earlier, driven by research and development expenses of $107.1 million and general and administrative expenses of $20.9 million. Cash, cash equivalents and investments totaled $351.3 million.
In August 2026, MapLight agreed to a $150.0 million private placement of common stock and pre-funded warrants. Management states that existing cash, cash equivalents and investments, together with expected private placement proceeds, are expected to fund operations through 2028.
MapLight Therapeutics, Inc. entered into a private placement with institutional investors to sell 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 shares at $11.38 per share (and $11.3799 per pre-funded warrant), for anticipated gross proceeds of approximately $150.0 million before fees. Each pre-funded warrant is exercisable at $0.0001 per share and does not expire, subject to beneficial ownership limits.
A Registration Rights Agreement requires MapLight to file resale registration statements within 30 days of closing and achieve effectiveness by specified deadlines, with liquidated damages of 1.0% per 30 days on invested amounts if it fails to meet those timelines, subject to caps. Cash, cash equivalents and investments were $351.3 million as of June 30, 2026, and together with the private placement are expected to extend the cash runway through 2028, including projected readouts for the VISTA and ZEPHYR-2 trials.
MapLight reported positive Phase 2 ZEPHYR results for ML-007C-MA in schizophrenia, including meeting the primary PANSS endpoint, a potentially differentiating cognitive signal, and a favorable tolerability profile, supporting advancement into registrational Phase 3 ZEPHYR-2. For the quarter ended June 30, 2026, the company recorded a net loss of $60.2 million, driven by research and development expenses of $53.4 million as it advances its CNS pipeline.
Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, Inc., reported selling 22,082 shares of Voting Common Stock on August 3, 2026 at a weighted average price of $12.54 per share, in transactions ranging from $12.12 to $12.99, pursuant to a Rule 10b5-1 trading plan adopted on December 29, 2025. Following this sale, Woodruff directly holds 202,380 shares of the company’s common stock.
Catalyst4, Inc., together with Robert Brown, Ekemini Riley and Mark Vorsatz, reports beneficial ownership of 20,906,689 shares of MapLight Therapeutics, Inc. common stock, representing 47.9% of the issuer’s voting common stock outstanding as of July 27, 2026.
Catalyst4 holds these shares with sole voting and dispositive power, while the three individuals share voting and dispositive power over the same shares. Over the last 60 days, Catalyst4 acquired 1,209,225 shares in multiple open market transactions for an aggregate purchase price of approximately $15.3 million, funded from its working capital with no borrowed funds or other financing. These additional purchases constitute a material increase in the reporting group’s ownership percentage compared with an earlier Schedule 13D filed in November 2025.
Maplight Therapeutics, Inc. has a filing by James Lillie indicating a proposed sale of up to 22,082 shares of common stock through Jefferies LLC, with an aggregate market value of $287,507.64. The shares relate to vested RSUs dated July 18, 2025, and are listed for NASDAQ trading on or after August 3, 2026.
The filing also lists prior sales of Maplight common stock by James Lillie over the past three months, including transactions such as 24,811 shares sold for $713,661.87 on May 6, 2026, and several smaller trades with specified share counts and dollar amounts.